Sionna Therapeutics shares drop after cystic fibrosis drug trial misses endpoint

What happened

Sionna Therapeutics, Inc. (NASDAQ: SION) announced on August 10, 2026, that its experimental drug SION-719 did not meet the key activity endpoint in a Phase 2a clinical trial. The trial tested SION-719 as an add-on to Trikafta, a standard treatment for cystic fibrosis, and measured reduction in sweat chloride as the primary endpoint. The company said it is discontinuing the SION-719 add-on program.

According to a company press release and reports from STAT News and Stock Titan, the trial missed its key endpoint. Sionna noted that potential confounders may have affected the results, but the company decided not to advance the program. The drug was generally well tolerated when given with Trikafta for 14 days.

Shares of Sionna fell sharply following the announcement, dropping as much as 92% in early trading. The stock closed at $6.46, down from a previous close of $6.03, a change of about 7.1% on the day, but the intraday collapse was much larger, per finance news sites.

Company background

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, a genetic disorder that affects the lungs and other organs. Its lead program, SION-719, was being tested as a potential add-on to existing CF therapies.

The company also reported its second quarter 2026 financial results on the same day, posting a net loss of approximately $29.9 million. Sionna ended the quarter with $268.3 million in cash, according to Stock Titan.

What this means

This is a Phase 2a trial, an early-stage study that tests whether a drug shows enough activity to justify further development. The key endpoint, sweat chloride reduction, is a direct measure of how well a CF treatment restores the function of the faulty protein that causes the disease. A miss on this endpoint means the drug did not show the expected biological effect.

Trikafta, made by Vertex Pharmaceuticals, is a combination therapy that has transformed CF care. SION-719 was being tested as an add-on to Trikafta, meaning it would be used on top of the current standard of care.

Discontinuing a program after a failed Phase 2a trial is a common outcome in drug development. The company has other assets, but this setback is significant for a clinical-stage biotech whose lead candidate has now failed.

The press release did not specify what Sionna plans to do next with its pipeline, and the sources do not provide details on other ongoing programs.